Effect of YM-254890, a specific G[alpha]q/11 inhibitor, on experimental peripheral arterial disease in rats.
Uemura, Toshio a,1; Takamatsu, Hajime a,1; Kawasaki, Tomihisa a,*; Taniguchi, Masatoshi b; Yamamoto, Eisaku b; Tomura, Yuichi a; Uchida, Wataru a; Miyata, Keiji a
[Article]
European Journal of Pharmacology.
536(1):154-161, April 2006.
(Format: HTML, PDF)
The protective effect of YM-254890, a specific G[alpha]q/11 inhibitor, on laurate-induced peripheral arterial disease in rats was compared with those of prostaglandin E1 (PGE1), beraprost, and clopidogrel. YM-254890 inhibited ADP-induced ex vivo rat platelet aggregation at a dose of 3[mu]g/kg. Furthermore, YM-254890 strongly inhibited phenylephrine-, serotonin- and endothelin-1-induced contractions in the rat aorta, and improved dermal blood flow after the laurate injection. The intra-arterial single bolus administration of YM-254890 15min after the laurate injection dose-dependently inhibited the progression of the lesion, with significance, at 3[mu]g/kg without affecting systemic blood pressure. PGE1 and beraprost, when administered before the laurate injection, were effective, but their potencies were less than that of YM-254890. Clopidogrel significantly suppressed lesion progression when administered at 30mg/kg twice a day for 3days, which completely inhibited platelet aggregation. These results suggest that the local administration of YM-254890 may be useful for treating peripheral arterial disease.
(C) 2006Elsevier, Inc.